AI in clinical trials: How the tech is serving pharma’s riskiest bet
From deal activity to top investors, we analyze the shifting landscape for AI in clinical trials to determine how the tech is transforming drug development for the better.
From deal activity to top investors, we analyze the shifting landscape for AI in clinical trials to determine how the tech is transforming drug development for the better.
In this webinar, our expert breaks down AI’s impact across the entire R&D pipeline – from discovery to FDA approval.
In 2025 so far, tech companies acquired for $100M or more had just 100 employees at the median. We break down the quarter's most efficient exits and which startups could be next.
Using CB Insights data, we highlight 6 predictions that pose disruption risks for insurance giants and emerging players.
From clinical operations to drug development, we mapped 85+ startups bringing generative AI to the healthcare and life sciences industries.
We mined the CB Insights database to map 170+ AI agent startups across 26 categories. We also provide an outlook on AI agents’ progress, limitations, and future directions.
Chatbots’ record quarter, artificial emotional intelligence, and more from the CB Insights newsletter.
From increasing specialization to rising infrastructure markets, here’s where the opportunities lie across the AI agent landscape.